GSKs Licensor Hansoh Pharma Reports Positive Phase III Results for Ris-Rez in China

In July 2026, Phase III clinical trial findings for Ris-Rez, an experimental B7-H3 targeted antibody drug combination (ADC) created to treat patients with recurrent small cell lung cancer in China, were reported by GSK's licensing partner, Hansoh Pharma. The ARTEMIS-008 study’s main goal was effectively accomplished when the treatment showed a statistically significant increase in overall survival when compared to traditional chemotherapy. Additionally, positive results were seen in several secondary clinical endpoints, supporting the therapy's potential to be a significant treatment option for individuals with this extremely aggressive illness.

Due to its quick progression and frequent recurrence following first therapy, small cell lung cancer is one of the most difficult types of lung cancer. Even while chemotherapy is still the most common treatment for patients with relapsed cancer, many people only receive modest long-term improvements, which highlights the urgent need for additional potent therapeutic options. The favorable outcomes of the ARTEMIS-008 study demonstrate how targeted treatments can increase survival while providing a more focused therapeutic strategy than traditional chemotherapy.

Antibody-drug conjugate technology, which combines potent anti-cancer medications with the targeting potential of monoclonal antibodies, was used in the development of Ris-Rez. The B7-H3 protein, which is frequently present on the surface of a number of solid tumors, is the specific target of the treatment. The treatment limits exposure to healthy tissues while delivering its therapeutic payload directly to the tumor after it has been adhered to cancer cells. The goal of this focused strategy is to lessen many of the adverse effects of conventional chemotherapy while increasing therapeutic efficacy.

Chinese patients whose small cell lung cancer had advanced after prior treatment were enrolled in the Phase III ARTEMIS-008 experiment. Overall survival was longer for those on Ris-Rez than for those on conventional chemotherapy. Additionally, the treatment improved the objective response rate and progression of free survival, suggesting improved disease management during treatment. Additionally, no unanticipated adverse events were found during the study, and the safer profile remained consistent with prior clinical findings, according to the researchers.

The study is a significant development for oncology research on antibody drug conjugates. It is one of the first late-stage clinical trials to show that a B7-H3-targeted ADC improves overall survival in patients with small cell lung cancer that has relapsed. The results give more evidence for the use of antibody-drug conjugates in the treatment of aggressive malignancies with few available treatments and bolster trust in targeted drug delivery technology.

Following the successful trial, Hansoh Pharma wants to submit the clinical data to Chinese regulatory authorities to support marketing approval for Ris-Rex. At the same time, GSK wants to continue the worldwide development program to examine the medication in other countries and across multiple tumor types. The businesses believe that expanding clinical studies could help establish the treatment as a new option for people with difficult-to-treat tumors beyond small cell lung cancer.

Advancements in antibody engineering, biomarker research, and precision medicine are revolutionizing cancer care by enabling medications that specifically target cancer cells while protecting healthy tissue. The results of the ARTEMIS-008 study indicate how next-generation antibody-drug conjugates might improve treatment outcomes and may stimulate greater investment in targeted oncology research. As additional clinical studies are completed, B7H3-targeted medicines could play a crucial role in expanding therapy choices for individuals with advanced solid malignancies.

Impact on the Healthcare Industry

According to Precedence Research, by enhancing cancer treatment outcomes, the growing use of biologics, precision medicine, and targeted medicines is revolutionizing the healthcare sector. More medical professionals are concentrating on treatments that minimize harm to healthy tissues while specifically targeting cancer cells. Ris-Rez's good Phase III findings demonstrate the expanding use of antibody drug conjugates in the treatment of aggressive malignancies such as small cell lung cancer. It is anticipated that these clinical developments would spur cancer research, promote more funding for targeted therapies, and increase patient access to cutting-edge treatment options globally.

Impact on the Antibody Drug Conjugates Market

The global antibody drug conjugates market size is calculated at USD 12.69 billion in 2025 and is predicted to increase from USD 14.09 billion in 2026 to approximately USD 34.80 billion by 2035, expanding at a CAGR of 10.61% from 2026 to 2035.

According to Precedence Research, the market for antibody drug conjugates is expanding due to the growing need for tailored cancer treatments, ongoing advancements in antibody engineering, and an increase in regulatory approvals. The therapeutic promise of B7-H3 targeted ADCs in treating hard-to-manage malignancies is further supported by the favorable Phase III outcomes of Ris-Rez. Positive clinical results are anticipated to boost the uptake of next-generation targeted medicines in the global cancer market, stimulate more research, and increase investment in ADC development.

Impact on the Lung Cancer Therapeutics Market

The global lung cancer therapeutics market size is valued at USD 35.37 billion in 2025 and is predicted to increase from USD 38.23 billion in 2026 to approximately USD 76.65 billion by 2035, expanding at a CAGR of 8.04% from 2026 to 2035.

According to Precedence Research, the market for lung cancer medicines is expanding due to the rising prevalence of lung cancer, the increased use of precision oncology, and the creation of new targeted therapies. Targeted antibody-drug conjugates have the potential to increase survival in patients with recurrent small cell lung cancer who have few therapy alternatives, as evidenced by the promising Phase III findings of Ris-Rez. Advanced targeted therapies are anticipated to enhance treatment outcomes and propel future market expansion as pharmaceutical companies continue to invest in cutting-edge oncology medications.

The positive Phase III results from the ARTEMIS-008 trial represent an important step in the development of Ris-Rez. We look forward to working with regulatory authorities and advancing the global clinical development of this promising B7-H3-targeted antibody-drug conjugate to bring a new treatment option to patients with small cell lung cancer," said Tony Wood, Chief Scientific Officer, GSK.

About GSK

GSK is a multinational biopharmaceutical business that specializes in creating cutting-edge medications and vaccines for immunology, infectious illnesses, cancer, and respiratory conditions. One of the top Chinese pharmaceutical companies, Hansoh Pharma, specializes in central nervous system illnesses, metabolic diseases, infectious diseases, and oncology. The firms are accelerating the development of novel targeted treatments to enhance treatment outcomes for cancer patients globally through their strategic partnership.